A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A
NCT ID: NCT06932705
Last Updated: 2025-04-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
48 participants
INTERVENTIONAL
2025-04-30
2025-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117A
NCT07152873
A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337
NCT03346187
Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product
NCT05234775
A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B
NCT05202405
Pharmacokinetics and Safety of HCP1105 and Co-administration of HGP0918, HGP0816 in Healthy Male Volunteers
NCT02941796
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequence A (RT)
Period 1: Reference (PA-111A), Period 2: Test (PA-111)
PA-111
PA-111 1Tab., Per Oral
PA-111A
PA-111A 1Capsule., Per Oral
Sequence A (TR)
Period 1: Test (PA-111), Period 2: Reference (PA-111A),
PA-111
PA-111 1Tab., Per Oral
PA-111A
PA-111A 1Capsule., Per Oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PA-111
PA-111 1Tab., Per Oral
PA-111A
PA-111A 1Capsule., Per Oral
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The Age equal to or greater than 19 in healthy volunteers at the time of screening visit
Exclusion Criteria
* Other exclusions applied
19 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Addpharma Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
H Plus Yangji Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PA-111BE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.